Refisolone

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Refisolone ( , ; developmental code names PH-80, Salubrin, and ORG-39479), also known as 10-hydroxy-16α,17α-epoxyestr-4-en-3-one, is a vomeropherine (pherine) which is under development for the treatment of hot flashes, migraine, and premenstrual dysphoric disorder (PMDD). It is taken intranasally as a nasal spray. The pharmacology of refisolone has been studied and reported. The drug is under development by Pherin Pharmaceuticals and VistaGen Therapeutics, with the former having been acquired by the latter in 2023. As of December 2025, refisolone is in phase 2 clinical trials for all indications. However, a phase 3 trial of refisolone for PMDD is also reported to have been registered in 2015, though its status is listed as unknown.

Refisolone ( , ; developmental code names PH-80, Salubrin, and ORG-39479), also known as 10-hydroxy-16α,17α-epoxyestr-4-en-3-one, is a vomeropherine (pherine) which is under development for the treatment of hot flashes, migraine, and premenstrual dysphoric disorder (PMDD). It is taken intranasally as a nasal spray. The pharmacology of refisolone has been studied and reported. The drug is under development by Pherin Pharmaceuticals and VistaGen Therapeutics, with the former having been acquired by the latter in 2023. As of December 2025, refisolone is in phase 2 clinical trials for all indications. However, a phase 3 trial of refisolone for PMDD is also reported to have been registered in 2015, though its status is listed as unknown.

See also

List of neurosteroids § Pheromones and pherines List of investigational sex-hormonal agents List of investigational PMS/PMDD drugs List of investigational headache and migraine drugs Fasedienol (PH94B; Aloradine) Itruvone (PH10)

References

External links

Refisolone (PH80) - Vistagen Therapeutics

Text derived from https://en.wikipedia.org/w/index.php?oldid=1342905761 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

6 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.